Virology

ViroLogic, Pfizer, expand agreement to support new HIV drug discovery and development efforts

Published in Vaccine Weekly, July 24th, 2002

ViroLogic, Inc., (VLGC) announced that the company has signed an expanded agreement with Pfizer, Inc., (PFE) to use ViroLogic's novel HIV resistance testing technology for Pfizer's HIV drug discovery and development programs.

The new agreement covers work performed for all of Pfizer's global research and development sites worldwide.

ViroLogic has developed technologies to assess drug resistance among a number of antiretroviral therapies in both preclinical and clinical studies including PhenoSense HIV, GeneSeq, PhenoSenseGT, PhenoSense HIV Entry, and PhenoScreen.

"This expanded agreement highlights how ViroLogic can serve as the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-07-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry